Line-Related Thrombosis: How Long to Anticoagulate After?
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared on LinkedIn:
Important clinical update on catheter-related thrombosis management
As clinicians, we often face questions about anticoagulation duration after catheter removal. The evidence suggests:
- NCCN guidelines recommend a minimum 3-month treatment for thrombosis, particularly in active malignancy
- Emerging evidence shows 1-month regimens may be sufficient in selected cases, with promising outcomes
- Patient-specific factors matter: cancer remission status significantly reduces recurrence risk (2.3%)
Key considerations include balancing thrombosis recurrence (4.8% at 1 year) against major haemorrhage risks (2.8-4.9%)
What’s your experience with anticoagulation duration in these cases? Would love to hear colleagues’ perspectives.”
Read the full review post here.
Review Post: For catheter or line-related thrombosis where removal is necessary, how long should anticoagulation be continued?
Author: Abdul Mannan
Stay informed on all guideline updates with Hemostasis Today.
-
Oct 13, 2025, 03:53Ganesh Mohan is Organising a Webinar to Improve Awareness About Thrombophilia on World Thrombosis Day
-
Oct 13, 2025, 02:47Thomas Reiser: Don't Miss This ISTH Research Recap with Robert Sidonio, Cedric Hermans and Michael Makris
-
Oct 12, 2025, 15:39Renjith Vijayakumar Selvarani: A Heart Attack Isn’t Just a Health Scare — It’s a Medical Emergency
-
Oct 12, 2025, 11:28Is it time for GLP1 receptor agonists in VTE care?
-
Oct 12, 2025, 11:26WFH: Women and Girls with Bleeding Disorders
-
Oct 13, 2025, 03:32Wolfgang Miesbach: This Study from Children's Hospital of Philadelphia Provides Crucial Insights Into Elevidys
-
Oct 13, 2025, 02:43Lukas Meyer and Colleagues on Reperfusion-dependent Treatment Effects of Thrombectomy in Large Ischemic Infarcts
-
Oct 12, 2025, 10:14Hatim Lokhandwala: Landmark HI-PRO Trial Redefines VTE Treatment Guidelines
-
Oct 12, 2025, 07:28Roberta Gualtierotti: rFVIIIFc and rFIXFc Ensured Effective Haemostasis and Favourable Safety in Major Orthopaedic Surgery
-
Oct 12, 2025, 01:32Evaluating Drug–Drug Interactions in Cancer Patients Receiving Anticoagulants and Antineoplastics
-
Oct 13, 2025, 02:46Flora Peyvandi: First Proposed Blood Test for Chronic Fatigue Syndrome - What Scientists Think
-
Oct 13, 2025, 02:44Silvio Maresca: Honored to be part of this international research project - ThrombUS+
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 13, 2025, 03:44Jorge Monge: It Was An Honor to Take Part in the 3rd EBA Workshop on Rare Blood Provision
-
Oct 13, 2025, 03:15Arun V. J: They Chose Death Over A Blood Transfusion — And Here’s Why I Stopped Judging Them
-
Oct 13, 2025, 03:13Rahaf Ajaj: The Persistent Gender Gap in Nobel Prizes - A Call for Greater Inclusion
-
Oct 13, 2025, 02:50Emmanuel J Favaloro: Again Promoting World Thrombosis Day - October 13
-
Oct 12, 2025, 07:38Antonio Vega With Incredible Team Led by the Great Dr Majluf